Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront.
Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...
The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...
Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...
Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...
Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) ...
The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...
Quest Diagnostics will take over the kidney-focused lab testing portfolio of the dialysis giant Fresenius Medical ...
AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...